The Worldwide Multiplex Assay Industry is Expected to Reach $4 Billion by 2027


Dublin, May 18, 2022 (GLOBE NEWSWIRE) -- The "Global Multiplex Assay Market Size, Share & Industry Trends Analysis Report By Product, By Type, By End user, By Application (Research & Development, Clinical Diagnostics & Others), By Regional Outlook and Forecast, 2021-2027" report has been added to's offering.

The Global Multiplex Assay Market size is expected to reach $4 billion by 2027, rising at a market growth of 9.8% CAGR during the forecast period.

A multiplex assay is a process that detects and quantifies many analytes such as biomolecules, proteins, cytokines, growth factors, and chemokines at the same time. In comparison to traditional approaches like ELISA, this assay is used to amplify many objectives in a polymerase chain reaction (PCR) and capture more details from minute amounts of proteins or other analytes in less time. Pathogen identification, RNA detection, gene detection analysis, linkage analysis, mutation analysis, and forensic studies all use multiplex assays.

Running numerous tests means there may be little differences within every run, which could affect the results. Running a single experiment prevents this fluctuation from having a large impact, thus any differences in the protein found to be more likely to indicate genuine relative abundance within the sample. One such disease is sepsis, which is defined by a shift in the levels of pro-inflammatory cytokines.

Certain chemicals, some of which have been explored as possible medicinal medications, can also alter cytokine levels. As a result, having a system that can assess the levels of many cytokines at the same time is advantageous. Each bead had captured antibodies for the above cytokines and was differentiated by the ratio of dye added in a bead-based approach.

In addition, high-throughput multiplex detection techniques are used to evaluate a large number of analytes such asnucleic acid assays, immunoassays, enzyme assays, or receptor ligands, in a single biological sample in a fast, sensitive, and specific manner. These methods allowthe analysis of a huge number of samples in one go.

COVID-19 Impact Analysis

The COVID-19 pandemic has wreaked havoc on healthcare workflows all around the world. Numerous industries, including plenty of sub-domains of health care, have been compelled to temporarily shut down their production facilities because of the disease. Since multiplex assays are used to diagnose coronaviruses, there has been a substantial demand for multiplex SARS-CoV-2 assays, such as multiplex point-of-care assays, which have helped the multiplex assay market grow during the pandemic. The link of COVID-19 with multiple hazardous disorders increased the utilization of multiplex assays across the market.

In addition, to address the growing demand of the high volume of testing, several businesses got FDA emergency use authorization for their COVID-19 multiplex assays. However, the companies had to deal with several operational issues that hindered their commercial operations throughout the lockdown.

Market Growth Factors:

Increasing popularity of companion diagnostics

Companion diagnostics method is rapidly emerging and being utilized in therapeutics. A companion diagnostic is a diagnostic test that is used in conjunction with a therapeutic drug to determine whether the specific personalized medicine is appropriate for a particular person. Companion diagnostics assays can be conducted on a tissue biopsy or a blood sample utilizing various genomic or protein-based technologies such as next Generation Sequencing, qPCR, and Immunohistochemistry. In the case of cancer, a companion diagnostic test can determine whether a patient's tumor has a specific genetic aberration, such as a mutation, or changed protein expression, that predicts better therapeutic medication efficacy.

Increasing adoption of multiple assays

There is an increased usage of multiplex assays in companion diagnostics, as well as their advantages over singleplex & classical assays is the result of the growing prevalence of chronic diseases. The advantage of multiplex assays over singleplex tests, which includes lower reaction tie, chemicals, and analyte concentration, allows for faster assay results and the handling of unusual samples (low concentration sample). The high frequency of infectious and chronic diseases creates greater market potential through increasing demand for multiplex assays.

Marketing Restraining Factor:

Rising equipment costs and stringent regulations and standards

Multiplex assays comprise the potential to bring a new evolution across the healthcare industry and can play a major role in the developments and enhancements in medications that are being utilized in the treatment of numerous diseases and disorders such as cancer and neurological diseases. However, the equipment that is employed in the utilization of multiplex assays is very costly. Due to the higher cost of the equipment, the researchers or healthcare institutes that comprise lesser financial power is expected to find it difficult to purchase and employ these products.

Key Topics Covered:

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals and Trials
3.2.4 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, May - 2021, Oct) Leading Players

Chapter 4. Global Multiplex Assay Market by Product
4.1 Global Reagents & Consumables Market by Region
4.2 Global Instruments & Accessories Market by Region
4.3 Global Software & Services Market by Region

Chapter 5. Global Multiplex Assay Market by Type
5.1 Global Protein Based Multiplex Assays Market by Region
5.2 Global Nucleic Acid-Based Multiplex Assay Market by Region
5.3 Global Others Market by Region

Chapter 6. Global Multiplex Assay Market by End User
6.1 Global Pharmaceutical & Biotechnology Companies Market by Region
6.2 Global Research Institutes Market by Region
6.3 Global Clinical Laboratories Market by Region
6.4 Global Hospitals Market by Region

Chapter 7. Global Multiplex Assay Market by Application
7.1 Global Research & Development Market by Region
7.2 Global Clinical Diagnostics Market by Region
7.3 Global Companion Diagnostics Market by Region

Chapter 8. Global Multiplex Assay Market by Region

Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Bio-Rad laboratories, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements: Product Launches and Product Expansions: Approvals and Trials:
9.3 Becton, Dickinson and Company
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements: Product Launches and Product Expansions:
9.4 Seegene, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 Recent strategies and developments: Approvals and Trials: Geographical Expansions:
9.5 Randox Laboratories Limited
9.5.1 Company Overview
9.6 Illumina, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expense
9.6.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements:
9.7 Qiagen N.V.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements:
9.8 DiaSorin S.p.A. (Luminex Corporation)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments: Partnerships, Collaborations, and Agreements: Approvals and Trials:
9.9 Abcam plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.10. Meso Scale Diagnostics LLC
9.10.1 Company Overview

For more information about this report visit


Contact Data